Allergy-assisted passive immunotherapy: Harnessing IgE-mediated responses for cancer treatment

Allergy-assisted passive immunotherapy proposes an anti-tumor strategy by transferring allergen-specific immunoglobulin E (IgE) antibodies from atopic donors to cancer patients via transfusion, followed by controlled allergen exposure to induce localized degranulation and inflammation within the tumor microenvironment. This review assesses the biological plausibility, potential mechanisms, and safety considerations of allergy-assisted passive immunotherapy - emphasizing its applicability to immunocompromised patients. While promising, the approach requires rigorous clinical validation.